person · Reporting owner

MCKEON BRIAN P

Disclosed activity across 4 companies

Tapewire entity: 38418
SEC CIK: 0001219445

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	May 20, 2026	May 23, 2026
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Director	June 12, 2026	June 15, 2026
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	EVP, CFO and Treasurer	February 14, 2025	February 19, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 20, 2026 · Filed May 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	38,536	Ending reported balance After 2026-05-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 40,011 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 38,536
Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20	Direct	11,538	Reported balance After 2026-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	5,409	Reported balance After 2026-05-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F4: This award is fully vested in accordance with its terms.
Ordinary SharesSEC Table I · non-derivative	IndirectBy the Brian P. McKeon Trust	10,000	Reported balance Holding disclosure · report date 2026-05-20 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 10,000 F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.

F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

F4: This award is fully vested in accordance with its terms.

DENTSPLY SIRONA Inc.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy a Trust	10,000	Reported balance After 2026-06-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-06-12 · Purchase · Acquired 10,000 · Balance 10,000
Common StockSEC Table I · non-derivative	Direct	28,887	Reported balance Holding disclosure · report date 2026-06-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 28,887

IDEXX LABORATORIES INC /DE

Report date February 14, 2025 · Filed February 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,208.5926	Reported balance After 2025-02-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-02-14 · Exercise / conversion · Acquired 252 · Balance 31,208.5926 F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.
Common StockSEC Table I · non-derivative	Direct	31,511.5926	Reported balance After 2025-02-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2025-02-14 · Exercise / conversion · Acquired 303 · Balance 31,511.5926
Common StockSEC Table I · non-derivative	Direct	31,819.5926	Reported balance After 2025-02-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2025-02-14 · Exercise / conversion · Acquired 308 · Balance 31,819.5926
Common StockSEC Table I · non-derivative	Direct	32,118.5926	Reported balance After 2025-02-14 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2025-02-14 · Exercise / conversion · Acquired 299 · Balance 32,118.5926
Common StockSEC Table I · non-derivative	Direct	31,549.5926	Reported balance After 2025-02-14 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2025-02-14 · Tax withholding · Disposed 569 · Balance 31,549.5926
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-02-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-02-14 · Exercise / conversion · Disposed 252 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	303	Reported balance After 2025-02-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-02-14 · Exercise / conversion · Disposed 303 · Balance 303 F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	615	Reported balance After 2025-02-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-02-14 · Exercise / conversion · Disposed 308 · Balance 615 F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	894	Reported balance After 2025-02-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-02-14 · Exercise / conversion · Disposed 299 · Balance 894 F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.
Common StockSEC Table I · non-derivative	Indirectby Estony McKeon Family, LLC	18,050	Reported balance Holding disclosure · report date 2025-02-14 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 18,050

Filing footnotes · ownership attribution and instrument terms

F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.

F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.

F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.

F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.

F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ATHENAHEALTH INC

Report date February 11, 2019 · Filed February 13, 2019

Section 16 reporting ended · disclosed 2019-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-02-11 transaction · row 1 1 source row Row 1 · 2019-02-11 · Disposition to issuer · Disposed 2,721 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes. F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes.

F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2020 Filed Aug 20, 2020 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	1,256	Not disclosed Strike: $79.54	Not disclosed	Disclosure SEC source: 0001567619-20-015832 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 628 shares of Issuer common stock that vested on February 14, 2020. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document
August 18, 2020 Filed Aug 20, 2020 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	1,880	Not disclosed Strike: $53.19	Not disclosed	Disclosure SEC source: 0001567619-20-015832 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,880 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 4,700 shares of Issuer common stock that vested in five annual installments beginning on January 1, 2015. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split"). Read SEC document
August 18, 2020 Filed Aug 20, 2020 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1,256	$79.54	$99,902.24	Disclosure SEC source: 0001567619-20-015832 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 18, 2020 Filed Aug 20, 2020 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1,880	$53.19	$99,987.80	Disclosure SEC source: 0001567619-20-015832 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	37,098	Not disclosed Strike: $62.00	Not disclosed	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,098 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F7 · derivative.exercise_date: Grant of option to buy 18,549 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	37,836	Not disclosed Strike: $53.19	Not disclosed	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,836 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 18,918 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on January 1, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	8,790	Not disclosed Strike: $43.68	Not disclosed	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,790 shares Expires 2023-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 4,395 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 8, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,049	$381.48	$1,163,118.49	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,596 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $380.792 to a high of $381.79 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	14,469	$380.12	$5,499,962.07	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,645 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $379.676 to a high of 380.674 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	37,209	$379.20	$14,109,701.17	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,114 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $378.63 to a high of $379.614 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	28,997	$377.84	$10,956,290.27	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,323 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	37,098	$62.00	$2,300,076.00	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	37,836	$53.19	$2,012,307.66	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 14, 2020 Filed Aug 18, 2020 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	8,790	$43.68	$383,947.20	Disclosure SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 05, 2020 Filed Aug 7, 2020 23:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	193	Not disclosed	Not disclosed	Disclosure SEC source: 0000874716-20-000033 · primary_doc.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,481 Underlying: Common Stock · 193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document
August 05, 2020 Filed Aug 7, 2020 23:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	97	$395.71	$38,383.87	Disclosure SEC source: 0000874716-20-000033 · primary_doc.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,596 Read SEC document
August 05, 2020 Filed Aug 7, 2020 23:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	193	$0.00	$0.00	Disclosure SEC source: 0000874716-20-000033 · primary_doc.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 43 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	435	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 13 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,674 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F9 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	505	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F9 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	459	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 Underlying: Common Stock · 459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F9 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	810	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,073 Underlying: Common Stock · 810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F9 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	628	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,883 Underlying: Common Stock · 628 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F9 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	1,731	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,511 Underlying: Common Stock · 1,731 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F9 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	17,813	Not disclosed Strike: $288.78	Not disclosed	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,813 Underlying: Common Stock · 17,813 shares Expires 2030-02-13 F9 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2021. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	979	$288.78	$282,715.62	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,457 Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	435	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	505	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	459	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	810	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2020 Filed Feb 20, 2020 02:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	628	$0.00	$0.00	Disclosure SEC source: 0001567619-20-004367 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 45 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2019 and December 31, 2019. Read SEC document
August 05, 2019 Filed Aug 7, 2019 22:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	961	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-015981 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,780 Underlying: Common Stock · 961 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning July 24, 2020. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning July 24, 2020. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning July 24, 2020. Read SEC document
August 05, 2019 Filed Aug 7, 2019 22:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	10,058	Not disclosed Strike: $260.07	Not disclosed	Disclosure SEC source: 0001567619-19-015981 · doc1.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,058 shares Expires 2029-08-04 F4 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning August 5, 2020. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	7,504	Not disclosed Strike: $44.05	Not disclosed	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,504 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy 3,752 shares of IDEXX Laboratories, Inc. common stock that became exercisable one installment on May 9, 2013 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	629	$248.79	$156,491.61	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,528 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. F8 · price: Represents the weighted average price of the shares sold ranging from a low of $248.765 to a high of $248.8475 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	5,771	$248.28	$1,432,818.69	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,157 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. F7 · price: Represents the weighted average price of the shares sold ranging from a low of $247.745 to a high of $247.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	225	$247.28	$55,638.25	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,928 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. F6 · price: Represents the weighted average price of the shares sold ranging from a low of $246.61 to a high of $247.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	375	$245.77	$92,164.73	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,153 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. F5 · price: Represents the weighted average price of the shares sold ranging from a low of $245.35 to a high of $246.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	300	$244.57	$73,371.99	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,528 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. F4 · price: Represents the weighted average price of the shares sold ranging from a low of $244.00 to a high of $244.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	204	$242.72	$49,513.98	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,828 F2 · shares: Sales were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. F3 · price: Represents the weighted average price of the shares sold ranging from a low of $242.42 to a high of $243.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
May 03, 2019 Filed May 6, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	7,504	$44.05	$330,513.68	Disclosure SEC source: 0001567619-19-009908 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 32 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	505	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,819 Underlying: Common Stock · 505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F9 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	459	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 13 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,324 Underlying: Common Stock · 459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F9 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	811	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,783 Underlying: Common Stock · 811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F9 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	629	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,594 Underlying: Common Stock · 629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F9 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	726	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,223 Underlying: Common Stock · 726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F9 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	2,175	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,949 Underlying: Common Stock · 2,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2015. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F9 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	483	Not disclosed Strike: $206.94	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	20,753	Not disclosed Strike: $206.94	Not disclosed	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,753 Underlying: Common Stock · 20,753 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	1,612	$206.94	$333,587.28	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,496 Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	505	$0.00	$0.00	Disclosure SEC source: 0001567619-19-004923 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.